HUTCHMED (China) Ltd
Tremor tracks 16 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- HCMHutchmed10Calm
Open-label Study of Surufatinib in Japanese Patients
FinishedPhase 1/236 patientsMain results: Sep 6, 2024 - HCMHutchmed10Calm
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
FinishedPhase 1/2348 patientsMain results: Nov 15, 2023 - HCMHutchmed10Calm
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
FinishedPhase 242 patientsMain results: Nov 30, 2024 - HCMHutchmed10Calm
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
FinishedPhase 261 patientsMain results: Dec 31, 2024 - HCMHutchmed0Calm
HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
Not started yetPhase 3210 patientsMain results: Mar 2032 - HCMHutchmed0Calm
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
FinishedPhase 2/3265 patientsMain results: Aug 28, 2026 - HCMHutchmed0Calm
HMPL-A830 in Solid Tumors
Signing up patientsPhase 1/2147 patientsMain results: May 23, 2029 - HCMHutchmed0Calm
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
FinishedPhase 261 patientsMain results: May 23, 2026 - HCMHutchmed0Calm
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Running, no new patientsPhase 3412 patientsMain results: May 30, 2028 - HCMHutchmed0Calm
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Signing up patientsPhase 1/2147 patientsMain results: Nov 30, 2028 - HCMHutchmed0Calm
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Signing up patientsPhase 1/2186 patientsMain results: Dec 31, 2028 - HCMHutchmed0Calm
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Signing up patientsPhase 2/3502 patientsMain results: May 31, 2028 - HCMHutchmed0Calm
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Signing up patientsPhase 3240 patientsMain results: Apr 30, 2028 - HCMHutchmed0Calm
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Signing up patientsPhase 2/3235 patientsMain results: Jun 30, 2028 - HCMHutchmed0Calm
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Signing up patientsPhase 3316 patientsMain results: Dec 31, 2028 - HCMHutchmed0Calm
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Signing up patientsPhase 3412 patientsMain results: Jan 8, 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.